XML 116 R58.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions (Details Textual) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2015
Dec. 31, 2015
Jun. 30, 2013
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Feb. 12, 2015
Apr. 02, 2013
Business Acquisition [Line Items]                
Potential future milestone payments   $ 2,800.0   $ 2,800.0        
Contingent consideration obligation       274.5 $ 0.0      
Maximum contingent consideration in the form of development and approval milestones   1,300.0   1,300.0        
Acquisition of TYSABRI rights       0.0 0.0 $ 3,262.7    
Deferred revenue   $ 55.7   $ 55.7 $ 120.9      
Convergence Pharmaceuticals                
Business Acquisition [Line Items]                
Cash portion of consideration $ 200.1              
Potential future milestone payments             $ 450.0  
Contingent consideration obligation 274.5              
Increase in contingent consideration liability 36.0              
Increase in goodwill $ 36.0              
Discount rate 2.00% 3.00%            
In-process research and development             424.6  
Other intangible assets             7.6  
TYSABRI product                
Business Acquisition [Line Items]                
Acquisition of TYSABRI rights     $ 3,250.0          
Deferred revenue               $ 84.4
Other intangible assets               $ 3,180.0
Future contingent payment for the first 12 months               12.00%
Future contingent payment for annual worldwide net sales up to $2.0 billion               18.00%
Future contingent payment threshold               $ 2,000.0
Future contingent payment for annual worldwide net sales that exceed $2.0 billion               25.00%
Raxatrigine | Convergence Pharmaceuticals                
Business Acquisition [Line Items]                
Potential future milestone payments             350.0  
Discount rate 11.00%              
Maximum contingent consideration in the form of development and approval milestones             145.0  
In-process research and development             200.0  
Neuropathic pain indications | Convergence Pharmaceuticals                
Business Acquisition [Line Items]                
Maximum contingent consideration in the form of development and approval milestones             415.0  
In-process research and development             $ 220.0